

DEXCOM INC.

ISIN: US2521311074 WKN: 252131107 Asset Class: Stock

Company

2021/02/24 22:00:00

Dexcom
CONTINUOUS GLUCOSE MONITORING

Price

405.64

USD

Difference

-0.28%(-1.14)



Contact Details

DEXCOM INC. Tel: +1-858-200-0200
Steve Pacelli Fax: -
Sequence Drive 6340 Web: <https://www.dexcom.com/>
92121 San Diego, CA E-mail: spacelli@dexcom.com

Company Profile

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,424,800,000	-	1,969,400,000	-	-	-
Common stock capital	-	100,000	-	100,000	-	-
Fixed assets	-	-	-	-	-	-
Equity capital of a company	-	1,826,500,000	-	882,600,000	-	-
Cash and cash equivalents	817,600,000	-	446,200,000	-	-	-
Accrued liabilities	-	-	-	88,500,000	-	-
Other assets	21,400,000	-	14,200,000	-	-	-
Current liabilities	-	614,100,000	-	360,200,000	-	-
Prepayments and accrued income	-	-	-	-	-	-
Non-current liabilities	-	-	-	-	-	-
Different income	-	-	-	1,700,000	-	-
Other liabilities	-	-	-	-	-	-
Total assets	4,290,500,000	4,290,500,000	2,395,000,000	2,395,000,000	-	-

Balance notes

	2020	2019	2018
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	5,500	3,900	2,800
Equity ratio	42.57%	36.85%	-%
Debt-equity ratio	134.90%	171.36%	-%

Others

	2020	2019	2018
Tax Expense Rate	-119.38%	2.98%	-%

DEXCOM INC.

ISIN: US2521311074

WKN: 252131107

Asset Class: Stock

Income statement

	2020	2019	2018
Turnover	1,926,700,000	1,476,000,000	-
Net income	493,600,000	101,100,000	-
EBIT	185,692,500	113,973,930	-
Operating income before taxes	225,000,000	104,200,000	-
Cash Flow	475,600,000	314,500,000	-
Net interest income	-	-33,900,000	-
Research and development expenses	359,900,000	273,500,000	-
Income taxes	-268,600,000	3,100,000	-
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	289,110	312,344	0

Board of Directors**Members of Management Board**

Kevin Sayer	Chairman of Board of Directors
Steven R. Altman	Member of Board of Directors
Richard Collins	Member of Board of Directors
Nick Augustinos	Member of Board of Directors
Mark Foletta	Member of Board of Directors
Kyle Malady	Member of Board of Directors
Karen Dahut	Member of Board of Directors
Jay Skyler, M.D.	Member of Board of Directors
Eric J. Topol, M.D.	Member of Board of Directors
Bridgette Heller	Member of Board of Directors
Barbara E. Kahn	Member of Board of Directors
Kevin Sayer	Chairman of Managing Board
Steven R. Pacelli	Member of Executive Committee
Sadie Stern	Member of Executive Committee
Rick Doubleday	Member of Executive Committee
Quentin Blackford	Member of Executive Committee
Patrick Murphy	Member of Executive Committee
Jake Leach	Member of Executive Committee
Don Abbey	Member of Executive Committee
Andrew K. Balo	Member of Executive Committee